All In Biotech

Free tool

FAERS Monitor: Acular Ls

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021528 or its brand name (Acular Ls, Ketorolac Tromethamine). Reports on generic versions are filed under their own applications.

Reports

4,453

Serious

2,549

57% of reports

Hospitalization

1,288

Death reported

258

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective491
  • drug hypersensitivity300
  • nausea255
  • headache248
  • pain241
  • dyspnoea227
  • fatigue219
  • treatment failure207
  • off label use163
  • vomiting161
  • diarrhoea150
  • product dose omission issue146
  • dizziness126
  • eye pain125
  • back pain124

Reports by year received

View as table
YearReports
200443
200571
200670
200769
200891
2009106
2010109
2011162
2012195
201369
201483
2015103
2016314
2017224
2018200
2019276
2020461
2021222
2022299
2023363
2024339
2025337
2026247

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,706 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
treatment failureSignal20711.810.42,044
eye painSignal12510.58.81,064
drug hypersensitivitySignal3007.36.61,647
back painSignal1242.52.1114
product dose omission issueSignal1462.32.0113
dyspnoea2271.91.798
headache2481.91.7102
pain2411.91.697
drug ineffective4911.81.6171
vomiting1611.61.438
nausea2551.51.447
fatigue2191.31.218
dizziness1261.21.04
diarrhoea1501.10.91
off label use1630.90.83

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.